ORCHESTRA BIOMED HOLDINGS INC.

NASDAQ: OBIO (Orchestra BioMed Holdings, Inc.)

Last update: 32 minutes ago

6.97

-0.15 (-2.11%)

Previous Close 7.12
Volume 551,845
Price / Sales 14.70
Price / Book 57.25
52 Weeks Range
3.46 (-50%) — 7.45 (6%)
Operating Margin (TTM) -2,179.84%
Diluted EPS (TTM) -1.77
Quarterly Revenue Growth (YOY) 40.00%
Total Debt/Equity (MRQ) 97.55%
Current Ratio (MRQ) 3.35
Operating Cash Flow (TTM) -54.06 M
Levered Free Cash Flow (TTM) -28.16 M
Return on Assets (TTM) -60.70%
Return on Equity (TTM) -179.12%

AIStockmoo Score

0.5
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Weak profitability. Ample short-term liquidity. Negative cash flow. info
Earns below its cost of capital. Returns on capital falling. info
From our AI technical analysis of the chart. info NA
Uptrend over the past year. Trading near its 52-week high. info
Price and its moving averages are lined up in an uptrend. Its main moving average is flat. Close to its rising moving average. Volume is heavier on up days. info
Candle Patterns info NA
Above its medium-term trend line. info
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Several insiders net buying recently. info
Institutions net +5.72% of shares in their latest 13F filings: 61 holders increased, 31 decreased (quarter to 30 Sep 2026). info
Short interest +11.0% from 31 Aug to 30 Oct 2026, 7 days to cover (FINRA). info
Market environment cautious. info
Sector lagging the market.
The pillars disagree, so the score is softened.
Price is high against its 52-week average. Down over 5 years. info
Trend up on all three terms. Short-term momentum rising. info
No clear signal from support and resistance. info
Final Score 0.53
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Orchestra BioMed Holdings, Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
OBIO - - - 57.25
TRML 1 B - - 4.76
VRDN - - - 7.26
VRCA - - - 15.60
TECH - 0.44% - 5.28
ABEO - - - 1.10

Select this tab to load the latest available analysis.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 21.81%
% Held by Institutions 49.62%
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
FAIN ERIC S 5.70 - 20,000 114,000
HOCHMAN DAVID P 5.70 - 5,000 28,500
PACITTI DAVID 5.70 - 20,000 114,000
TAYLOR ANDREW LAWRENCE 5.70 - 1,000 5,700
Aggregate Net Quantity 46,000
Aggregate Net Value ($) 262,200
Aggregate Avg. Buy ($) 5.70
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
TAYLOR ANDREW LAWRENCE Officer 09 Nov 2026 Buy (+) 1,000 5.70 5,700
HOCHMAN DAVID P Officer 09 Nov 2026 Buy (+) 5,000 5.70 28,500
PACITTI DAVID Director 09 Nov 2026 Buy (+) 20,000 5.70 114,000
FAIN ERIC S Director 09 Nov 2026 Buy (+) 20,000 5.70 114,000

Institutions

Institutional ownership: 41.73%

Positions Holders Shares
Increased 61 5,034,559
Decreased 31 1,386,397
New 27 1,437,879
Sold out 11 569,836

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 2,732,484 7.0
15 Oct 2026 2,552,988 9.7
30 Sep 2026 2,547,249 7.0
15 Sep 2026 2,372,557 6.6
31 Aug 2026 2,460,669 5.8
14 Aug 2026 2,383,854 13.1

FINRA short interest via Nasdaq, reported twice a month.

2 Positive 3 Negative 1 Neutral
Date Type Details
17 Nov 2026 Yahoo Finance Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
16 Nov 2026 Yahoo Finance Wall Street Analysts Think Orchestra BioMed Holdings, Inc. (OBIO) Could Surge 72.41%: Read This Before Placing a Bet
The mean of analysts' price targets for Orchestra BioMed Holdings, Inc. (OBIO) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
10 Nov 2026 Yahoo Finance Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +25.00% and -17.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
10 Nov 2026 Yahoo Finance Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
BACKBEAT Global Pivotal Trial evaluating AVIM Therapy completed enrollment and exceeded enrollment target, with a total of 349 patients randomized.BACKBEAT Trial primary endpoint data planned to be submitted for late-breaking presentation at the Heart Rhythm Society 2027 (“HRS 2027”).Medtronic…
05 Nov 2026 Yahoo Finance Orchestra BioMed Announces Pricing of Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
05 Nov 2026 Yahoo Finance Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device…
29 Oct 2026 Yahoo Finance Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels…
22 Oct 2026 Yahoo Finance Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq…
20 Oct 2026 Yahoo Finance OpenAI acquires Orchestra Bio to boost drug development AI, Axios reports
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .
01 Oct 2026 Yahoo Finance Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment targetCompany reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027 Data expected to support future marketing…
21 Sep 2026 Yahoo Finance Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
16 Sep 2026 Yahoo Finance Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO)…
15 Sep 2026 Yahoo Finance Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides…
02 Sep 2026 Yahoo Finance Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported…
27 Aug 2026 Yahoo Finance Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman…
20 Aug 2026 Yahoo Finance Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that Chairman and CEO David Hochman…
Show more

Recent Signals candle patterns and EMA crosses

▲ Bullish EMA cross 4 sessions ago · 11 Nov
Short term · EMA 7/20
The 7-day EMA crossed above the 20-day: short-term momentum turned up.

Technical Setup Medium

Trend order
Slope
Entry
Volume
Price and its moving averages are lined up in an uptrend. Its main moving average is flat. Close to its rising moving average. Volume is heavier on up days.
Nearest support: 6.36 – 6.62 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria